Kaplan-Meier analyses indicated that CRC patients with tumors harboring a higher RGL2 transcript exhibited poorer disease-free and overall survival rates in the GSE17537/GSE17536 CRC datasets (Figure 2B) and TCGA CRC database (Figure 2C), respectively. This evidence concerns the gene RGL2 and colorectal carcinoma.